What happened Researchers presenting at ENDO 2026 in Chicago on June 13, 2026 found that adults with obesity who started a GLP-1 receptor agonist drugs like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, or dulaglutide became noticeably less physically active after beginning treatment
Its important to select both a protein and a coffee that work well together and bring forward the right balance of sensory notes
[] GDM increases the risk of complications like fetal macrosomia, preeclampsia, and type 2 diabetes postpartum
Besides, LC mainly drafted the manuscript and assisted the implement of subsequent trial program
The honest conversation we need is around safety standards: if patients are going to do this anyway, what is the minimum guidance we should provide